Back to Search Start Over

Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients.

Authors :
Pignatti P
Ramirez GA
Russo M
Marraccini P
Nannipieri S
Asperti C
Torre FD
Tiri A
Gatti BM
Gurrado A
Meriggi A
Benanti G
Cilona MB
Pigatto P
Burastero SE
Dagna L
Yacoub MR
Source :
Vaccine [Vaccine] 2023 Jul 19; Vol. 41 (32), pp. 4693-4699. Date of Electronic Publication: 2023 Jun 15.
Publication Year :
2023

Abstract

Basophil activation test (BAT) can tackle multiple mechanisms underlying acute and delayed hypersensitivity to drugs and vaccines and might complement conventional allergy diagnostics but its role in anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine-related hypersensitivity is ill-defined. Therefore, 89 patients with possible hypersensitivity (56 % with delayed mucocutaneous manifestations) to anti-SARS-CoV-2 vaccines were tested with BAT for Macrogol 3350, DMG-PEG 2000, PEG 20000, polysorbate-80 and trometamol and compared to 156 subjects undergoing pre-vaccine BAT. A positive BAT was associated with delayed reaction onset (p = 0.010) and resolution (p = 0.011). BAT was more frequently positive to DMG-PEG 2000 than to other excipients in both groups (p < 0.001). DMG-PEG 2000 reactivity was less frequent in vaccine-naïve (6 %) than vaccinated subjects (35 %, p < 0.001) and associated with mRNA-1273 vaccination. DMG-PEG 2000 BAT might therefore have a diagnostic role in subjects with delayed hypersensitivity reactions. Natural immunity might be a key player in basophil activation.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2023 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1873-2518
Volume :
41
Issue :
32
Database :
MEDLINE
Journal :
Vaccine
Publication Type :
Academic Journal
Accession number :
37349223
Full Text :
https://doi.org/10.1016/j.vaccine.2023.06.039